Analyst
UBS
Equibles does not estimate personal net worth.
Matt is recorded as Analyst at UBS. Matt has spoken on 4 earnings calls across 3 companies, most recently for Allogene Therapeutics, Inc. on August 12, 2026. Those appearances were for Nuvation Bio Inc. (NUVB), Allogene Therapeutics, Inc. (ALLO) and Beam Therapeutics Inc. (BEAM). The companies whose calls Matt spoke on are classified in the Healthcare sector.
“I wanted to add, I saw you guys added an observational cohort to the Alpha 3 study, and I just wanted to ask about kind of the design of this cohort, maybe what the goal of it is, and kind of the questions you're helping to answer.”
“I wanted to ask on your expectations, just kind of for the trajectory cadence of patient uptake for the year, especially with maybe a competitor entering the market in the second line setting later in the year, how do you expect to see kind of the market shake out?”
“Maybe one of the next-gen sickle cell programs. It seems like in vivo has maybe leapfrogged escape in terms of priority. Could you just speak to what goes into choosing the right next-gen program for sickle cell and what gives you confidence in the InVivo program and the HSC targeting that you might use there.”
UBS
Analyst
Transcript header (unverified)
NUVB
Biotechnology · Healthcare
